BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10226097)

  • 1. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
    Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
    Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
    Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
    Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function.
    Szebeni J; Baranyi L; Sávay S; Bodó M; Milosevits J; Alving CR; Bünger R
    Am J Physiol Heart Circ Physiol; 2006 Mar; 290(3):H1050-8. PubMed ID: 16214844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.
    Őrfi E; Mészáros T; Hennies M; Fülöp T; Dézsi L; Nardocci A; Rosivall L; Hamar P; Neun BW; Dobrovolskaia MA; Szebeni J; Szénási G
    Int J Nanomedicine; 2019; 14():1563-1573. PubMed ID: 30880965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiopulmonary hemodynamic responses to the small injection of hemoglobin vesicles (artificial oxygen carriers) in miniature pigs.
    Sakai H; Suzuki Y; Sou K; Kano M
    J Biomed Mater Res A; 2012 Oct; 100(10):2668-77. PubMed ID: 22615268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
    Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
    Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
    Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
    J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity reactions to intravenous lipid emulsion in swine: relevance for lipid resuscitation studies.
    Bedocs P; Capacchione J; Potts L; Chugani R; Weiszhar Z; Szebeni J; Buckenmaier CC
    Anesth Analg; 2014 Nov; 119(5):1094-101. PubMed ID: 25126705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1.
    Szebeni J; Spielberg H; Cliff RO; Wassef NM; Rudolph AS; Alving CR
    Artif Cells Blood Substit Immobil Biotechnol; 1997 Jul; 25(4):347-55. PubMed ID: 9242930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C5a/C5ades-Arg-induced increase in blood pressure in the guinea pig: role of thromboxane.
    Fraser DG; Regal JF
    Immunopharmacology; 1990; 19(1):59-68. PubMed ID: 1968450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
    Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of the hemodynamic effects of iopromide-carrying liposomes in rats and pigs.
    Krause W; Gerlach S; Muschick P
    Invest Radiol; 2000 Aug; 35(8):493-503. PubMed ID: 10946977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
    Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
    J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
    Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model.
    Szebeni J; Bedőcs P; Urbanics R; Bünger R; Rosivall L; Tóth M; Barenholz Y
    J Control Release; 2012 Jun; 160(2):382-7. PubMed ID: 22421426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1.
    Szebeni J; Wassef NM; Hartman KR; Rudolph AS; Alving CR
    Transfusion; 1997 Feb; 37(2):150-9. PubMed ID: 9051089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
    Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
    Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
    Szebeni J; Storm G
    Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation and membrane lipids in lung vascular injury.
    Lundberg C; Gardinali M; Hugli TE
    Am Rev Respir Dis; 1987 Aug; 136(2):459-62. PubMed ID: 3619209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.